Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun 1;13(6):e0198184.
doi: 10.1371/journal.pone.0198184. eCollection 2018.

Efficacy and Tolerability of Old and New Drugs Used in the Treatment of Immune Thrombocytopenia: Results From a Long-Term Observation in Clinical Practice

Affiliations
Free PMC article

Efficacy and Tolerability of Old and New Drugs Used in the Treatment of Immune Thrombocytopenia: Results From a Long-Term Observation in Clinical Practice

Fabian Depré et al. PLoS One. .
Free PMC article

Abstract

Background: Many patients with immune thrombocytopenia (ITP) may require special attention and long-term treatment. Little is known on the efficacy and tolerability of the drugs used in practice.

Material and methods: We retrospectively reviewed the results of therapy of 400 patients with chronic ITP. All Patients were treated at our institution between 1996-2016 under consideration of guidelines, general recommendations, and individual aspects, including gender, age, weight, comorbidity, patient's medical history and bleeding risk.

Results: Treatment was not required in 25% of patients (n = 100) during observation. In treated patients (n = 300), the rate of patients that responded and tolerated treatment with prednisolone was 59% (52/88), with azathioprine 32% (29/90), with eltrombopag 49% (31/63), with romiplostim 59% 27/45, with IVIG (intravenous immunoglobulines) 75% (94/126), with anti-D 37% (19/52) and with dexamethasone 60% (25/42) patients. Eighteen treated patients (6%) entered sustained remission after treatment with various drugs. Twenty-six patients underwent splenectomy (Splx) resulting in sustained remission in 15 cases (60%). Only two patients remained refractory to Splx and to all used drugs.

Discussion: None of the currently available drugs used in the treatment of ITP are invariably safe and effective. Responses, the duration of response, intolerability, and the course of disease are unpredictable. Although the treatment of ITP has considerably improved in the recent years, the currently available drugs may rarely cure affected patients. The need for safe and effective therapy in ITP is evident. Optimal treatment decisions for each patient remains a challenge in many cases.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Patient and clinical characteristics.
Fig 2
Fig 2. Patients that just required controls due to mild ITP without any therapy during observation.

Similar articles

See all similar articles

Cited by 2 articles

References

    1. Whipple A.O. Splenectomy as a therapeutic measure in thrombocytopenic purpura haemorhagica. Surgery, Gynecology & Obstetrics. 1926; 42: 329–341.
    1. Wintrobe MM, Cartwright GE, Palmer JG, Kuhns WJ, Samuels LT. Effect of corticotrophin and cortisone on the blood in various disorders in man. AMA Arch Intern Med. 1951; 88: 310–36. - PubMed
    1. Burns CM. The History of Cortisone Discovery and Development. Rheum Dis Clin North Am. 2016; 42: 1–14. doi: 10.1016/j.rdc.2015.08.001 - DOI - PubMed
    1. Godeau B, Provan D, Bussel J. Immune thrombocytopenic purpura in adults. Curr Opin Hematol. 2007; 14: 535–56. doi: 10.1097/MOH.0b013e3282b9748f - DOI - PubMed
    1. Imbach P, Barandun S, d'Apuzzo V, Baumgartner C, Hirt A, Morell A et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981; 1: 1228–31. - PubMed

MeSH terms

Grant support

The authors received no specific funding for this work.

LinkOut - more resources

Feedback